Deadline: 15-Oct-2025
The Pfizer and the National Bleeding Disorders Foundation have partnered to launch the second round of the Education in the Era of Emerging Hemophilia Therapy initiative.
This program invites proposals for independent medical education projects that empower both patients and healthcare providers with the knowledge to navigate evolving treatment options for hemophilia.
The grant program is designed to provide equitable education for people living with hemophilia, enabling them to make evidence-based treatment choices. It also seeks to support physicians and multidisciplinary care teams in facilitating shared decision-making discussions that reflect the latest therapeutic advances. By focusing on education, the program aims to improve patient outcomes while fostering stronger collaboration between patients and healthcare professionals.
The National Bleeding Disorders Foundation, dedicated to research, education, and advocacy, brings its expertise in patient-centered initiatives to this collaboration. Pfizer, through its External Research & Grants program, will provide funding to independent education projects while ensuring the grant recipients retain full responsibility for program design, implementation, and execution. An expert review panel selected by the foundation will oversee project selection and foster a learning community among grantees.
This opportunity is open to healthcare institutions, professional schools, non-profits, professional societies, and other organizations committed to medical education. Applicants must be based in the United States, Puerto Rico, or Guam, and organizations, rather than individuals, are eligible to apply. Accredited providers are required for projects offering continuing education credits.
The focus of this round of funding is to educate communities on the rapidly evolving treatment landscape for hemophilia. Proposals should highlight shared decision-making approaches, address the needs of underserved populations, and incorporate perspectives from people living with hemophilia and their caregivers. Projects should reflect the diversity of the patient community, ensuring that cultural, racial, and geographic factors are meaningfully included.
A variety of educational formats are welcome, from conference sessions and live meetings to webinars, podcasts, online articles, videos, and interactive digital content. Initiatives that build knowledge over time, such as multi-activity or curriculum-based programs, are especially encouraged. Clinical research studies, however, are not within the scope of this opportunity.
The program has an estimated total budget of $90,000, with individual grants of up to $15,000 available. Award amounts will depend on the quality of proposals and the recommendations of the expert review panel. Funding will cover direct and indirect costs, with institutional overhead capped according to Pfizer’s policy.
This grant represents a vital chance to enhance understanding of hemophilia therapies at both the patient and professional level. By fostering inclusive, evidence-based education, the initiative seeks to prepare communities for the future of hemophilia care and to ensure that all individuals have access to the knowledge they need to make informed decisions.
For more information, visit Pfizer.
